Results from a post-hoc analysis of an investigational Phase II study found that Humira (adalimumab, AbbVie) induced significant response rate in adult patients with moderate to severe hidradenitis suppurativa (HS) after 16 weeks of therapy. Researchers used the HS-Physician Global Assessment (HS-PGA) to evaluate the clinical response of HUMIRA at 16 weeks. At 16 weeks, 9.6 percent of patients treated every other week, and 17.6 percent of patients treated weekly achieved an HS-PGA of clear, minimal, or mild, with at least a 2- grade improvement relative to baseline. The data were presented at the 22nd Congress of the European Dermatology and Venereology (EADV) meeting in Istanbul, Turkey.